Literature DB >> 29226325

LncRNA MALAT1 induces colon cancer development by regulating miR-129-5p/HMGB1 axis.

Qiong Wu1, Wen-Ying Meng1, Ying Jie2, Haijian Zhao3.   

Abstract

Recent studies have exhibited significant roles of lncRNAs in various tumors' development, including colon cancer. Our study focused on the biological roles of lncRNA MALAT1 in colon cancer. In our study, it was demonstrated that MALAT1 was upregulated in human colon cancer cell lines including Lovo, HCT116, SW480, and HT29 cells compared to the normal human intestinal epithelial HIEC cells. Moreover, we observed that miR-129-5p was downregulated in colon cancer cells with a significant increase of HMGB1 expression. Inhibition of MALAT1 can inhibit the proliferation of colon cancer SW480 and HCT116 cells and next, bioinformatics analysis was used to predict the target microRNA of MALAT1. miR-129-5p was identified and confirmed as a direct regulator of MALAT1 and it was shown that miR-129-5p mimics were able to restrain the progression of colon cancer cells. In addition, high motility group box protein 1 (HMGB1), was predicted as a mRNA target of miR-129-5p. Furthermore, we found that MALAT1 exerted its biological functions through regulating HMGB1 by sponging miR-129-5p in vitro. Silencing MALAT1 greatly inhibited HMGB1 expression which can be reversed by miR-129-5p inhibitors. It was indicated in our investigation that MALAT1 may serve as a competing endogenous lncRNA (ceRNA) to mediate HMGB1 by sponging miR-129-5p in colon cancer. Taken together, our results indicated that MALAT1/miR-129-5p/HMGB1 axis could be provided as an important prognostic biomarker in colon cancer development.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  HMGB1; MALAT1; colon cancer; miR-129-5p

Mesh:

Substances:

Year:  2018        PMID: 29226325     DOI: 10.1002/jcp.26383

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  69 in total

1.  miR-129-5p improves cardiac function in rats with chronic heart failure through targeting HMGB1.

Authors:  Na Xiao; Jun Zhang; Chao Chen; Yanfang Wan; Ning Wang; Jing Yang
Journal:  Mamm Genome       Date:  2019-10-23       Impact factor: 2.957

Review 2.  LncRNAs in ocular neovascularizations.

Authors:  Yacouba Cissé; Lang Bai; Min-Ting Chen
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

3.  Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis.

Authors:  Yan Wang; Quande Lin; Chunge Song; Ruojin Ma; Xiaojie Li
Journal:  Cell Cycle       Date:  2020-11-01       Impact factor: 4.534

4.  Molecular mechanism of miR-34b-5p and RNA binding protein HuR binding to lncRNA OIP5-AS1 in colon cancer cells.

Authors:  Yan Wang; Changkun Lin; Yang Liu
Journal:  Cancer Gene Ther       Date:  2021-05-21       Impact factor: 5.987

5.  LINC00958 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of oesophageal squamous cell carcinoma cells.

Authors:  Biqi Wang; Duo Tang; Zijia Liu; Qian Wang; Shan Xue; Zijie Zhao; Dongdong Feng; Chao Sheng; Jintao Li; Zhixiang Zhou
Journal:  PLoS One       Date:  2021-05-18       Impact factor: 3.240

Review 6.  HMGB1 as a therapeutic target in disease.

Authors:  Jiaming Xue; Joelle S Suarez; Michael Minaai; Shuangjing Li; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  J Cell Physiol       Date:  2020-10-26       Impact factor: 6.384

7.  Integrative analysis of ceRNA network reveals functional lncRNAs associated with independent recurrent prognosis in colon adenocarcinoma.

Authors:  Yinling Mao; Jiachen Lv; Li Jiang; Yihui Wang
Journal:  Cancer Cell Int       Date:  2021-07-05       Impact factor: 5.722

8.  Long noncoding RNA ILF3-AS1 aggravates papillary thyroid carcinoma progression via regulating the miR-4306/PLAGL2 axis.

Authors:  Zhaohui Zeng; Qiangfeng Teng; Jinhong Xiao
Journal:  Cancer Cell Int       Date:  2021-06-27       Impact factor: 5.722

Review 9.  Role of microRNA-129 in cancer and non-cancerous diseases (Review).

Authors:  Bingpeng Deng; Xuan Tang; Yong Wang
Journal:  Exp Ther Med       Date:  2021-06-30       Impact factor: 2.447

10.  Sevoflurane Suppresses Colon Cancer Cell Malignancy by Regulating circ-PI4KA.

Authors:  Suqing Sun; Peng Wang; Lijie Ren; Hongli Wang; Yanli Zhan; Shimin Shan
Journal:  Onco Targets Ther       Date:  2021-05-20       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.